PL3452039T3 - Leczenie zaburzeń utraty włosów deuterowanymi inhibitorami jak - Google Patents

Leczenie zaburzeń utraty włosów deuterowanymi inhibitorami jak

Info

Publication number
PL3452039T3
PL3452039T3 PL17793380.1T PL17793380T PL3452039T3 PL 3452039 T3 PL3452039 T3 PL 3452039T3 PL 17793380 T PL17793380 T PL 17793380T PL 3452039 T3 PL3452039 T3 PL 3452039T3
Authority
PL
Poland
Prior art keywords
deuterated
treatment
hair loss
jak inhibitors
loss disorders
Prior art date
Application number
PL17793380.1T
Other languages
English (en)
Polish (pl)
Inventor
Amanda T. Wagner
James V. Cassella
Philip B. Graham
Virginia BRAMAN
Vinita UTTAMSINGH
Jana VON HEHN
Colleen E. Hamilton
Original Assignee
Sun Pharmaceutical Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3452039(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries, Inc. filed Critical Sun Pharmaceutical Industries, Inc.
Publication of PL3452039T3 publication Critical patent/PL3452039T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17793380.1T 2016-05-04 2017-05-04 Leczenie zaburzeń utraty włosów deuterowanymi inhibitorami jak PL3452039T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US201762492758P 2017-05-01 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
PL3452039T3 true PL3452039T3 (pl) 2024-11-18

Family

ID=60203616

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17793380.1T PL3452039T3 (pl) 2016-05-04 2017-05-04 Leczenie zaburzeń utraty włosów deuterowanymi inhibitorami jak

Country Status (21)

Country Link
US (3) US10561659B2 (enExample)
EP (2) EP3452039B1 (enExample)
JP (3) JP7145080B2 (enExample)
KR (3) KR102810262B1 (enExample)
CN (1) CN109069493A (enExample)
AU (3) AU2017261286B2 (enExample)
BR (1) BR112018072339A2 (enExample)
CA (1) CA3022519A1 (enExample)
DK (1) DK3452039T3 (enExample)
ES (1) ES2988629T3 (enExample)
FI (1) FI3452039T3 (enExample)
HR (1) HRP20241345T1 (enExample)
HU (1) HUE068643T2 (enExample)
LT (1) LT3452039T (enExample)
MX (6) MX388054B (enExample)
PL (1) PL3452039T3 (enExample)
PT (1) PT3452039T (enExample)
RS (1) RS66006B1 (enExample)
SI (1) SI3452039T1 (enExample)
SM (1) SMT202400389T1 (enExample)
WO (1) WO2017192905A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3022519A1 (en) * 2016-05-04 2017-11-09 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CA3129096A1 (en) * 2019-02-06 2020-08-13 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
CA3196551A1 (en) * 2020-10-28 2022-05-05 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
EP4384175A1 (en) 2021-08-11 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CA3250876A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Ind Inc DOSAGE REGIMEN FOR TREATMENT WITH DEUTERATED JAK INHIBITORS
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
HRP20030873B1 (en) 2001-05-03 2006-04-30 F. Hoffmann - La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP2008514706A (ja) 2004-09-29 2008-05-08 コーディス・コーポレイション 安定非晶質ラパマイシン様化合物の薬学的投与形態
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
AU2006332726B2 (en) 2005-12-28 2012-12-13 Vertex Pharmaceuticals Incorporated. Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CN103370076A (zh) * 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CA2876306C (en) * 2012-06-15 2024-02-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
PE20151157A1 (es) 2012-11-15 2015-08-19 Incyte Corp Formas de dosificacion de ruxolitinib de liberacion sostenida
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
CA3022519A1 (en) 2016-05-04 2017-11-09 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors

Also Published As

Publication number Publication date
KR20230086814A (ko) 2023-06-15
CN109069493A (zh) 2018-12-21
US20200222408A1 (en) 2020-07-16
FI3452039T3 (fi) 2024-10-02
BR112018072339A2 (pt) 2019-02-19
AU2025213576A1 (en) 2025-08-21
MX2023002325A (es) 2023-03-22
MX2023002324A (es) 2023-03-22
KR20250070139A (ko) 2025-05-20
AU2017261286B2 (en) 2023-03-23
EP3452039B1 (en) 2024-07-03
AU2017261286A1 (en) 2018-11-22
AU2023201112B2 (en) 2025-05-08
EP3452039A4 (en) 2019-12-25
RS66006B1 (sr) 2024-10-31
EP4424367A3 (en) 2024-11-13
MX2018013347A (es) 2019-09-02
US20240423986A1 (en) 2024-12-26
KR102810262B1 (ko) 2025-05-19
US10561659B2 (en) 2020-02-18
PT3452039T (pt) 2024-10-07
HRP20241345T1 (hr) 2024-12-20
JP2019516684A (ja) 2019-06-20
MX388054B (es) 2025-03-19
MX2023002321A (es) 2023-03-22
KR20190003711A (ko) 2019-01-09
SI3452039T1 (sl) 2024-12-31
JP7586868B2 (ja) 2024-11-19
JP2022171838A (ja) 2022-11-11
JP2025026895A (ja) 2025-02-26
JP7145080B2 (ja) 2022-09-30
MX2023002323A (es) 2023-03-22
SMT202400389T1 (it) 2024-11-15
US12076323B2 (en) 2024-09-03
DK3452039T3 (da) 2024-10-07
HUE068643T2 (hu) 2025-01-28
ES2988629T3 (es) 2024-11-21
WO2017192905A1 (en) 2017-11-09
MX2021014175A (es) 2022-01-04
LT3452039T (lt) 2024-10-25
EP3452039A1 (en) 2019-03-13
EP4424367A2 (en) 2024-09-04
US20190160068A1 (en) 2019-05-30
CA3022519A1 (en) 2017-11-09
AU2023201112A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
SMT202400389T1 (it) Trattamento dei disturbi di perdita dei capelli con inibitori delle jak deuterati
ZA202006746B (en) Methods of treatment
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL267229A (en) Methods of treating ocular disorders
IL270781A (en) Treatment of depressive disorders
SG11201607881SA (en) Methods of treating nail and scalp psoriasis
IL270900A (en) Treatment of cutaneous disorders
HUE064403T2 (hu) A H3-ligandumok új terápiás alkalmazása
ZA201705847B (en) Treatment of pain
HUE062857T2 (hu) Készítmény hajnövekedési rendellenességek megelõzésére és kezelésére
IL256249A (en) The vehicle for treating hair loss and increasing its growth
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL265259A (en) Treatment of multiple sclerosis with chs-131
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
IL251862A0 (en) Combined treatment to delay hair loss
ZA202002910B (en) Treatment of skin disorders
GB201604359D0 (en) Treatment of tissue disorders
SG11202007642RA (en) Treatment of disorders with tasimelteon
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201700308D0 (en) Hair treatment methods
GB201602640D0 (en) Treatment of fibrotic disorders
GB201602641D0 (en) Treatment of fibrotic disorders
HK40006632A (en) Treatment of pain
PH32016001115S1 (en) Scalp massager